JP2017503011A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503011A5
JP2017503011A5 JP2016558549A JP2016558549A JP2017503011A5 JP 2017503011 A5 JP2017503011 A5 JP 2017503011A5 JP 2016558549 A JP2016558549 A JP 2016558549A JP 2016558549 A JP2016558549 A JP 2016558549A JP 2017503011 A5 JP2017503011 A5 JP 2017503011A5
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016558549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503011A (ja
JP6671292B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/070654 external-priority patent/WO2015095223A2/en
Publication of JP2017503011A publication Critical patent/JP2017503011A/ja
Publication of JP2017503011A5 publication Critical patent/JP2017503011A5/ja
Application granted granted Critical
Publication of JP6671292B2 publication Critical patent/JP6671292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016558549A 2013-12-16 2014-12-16 ペプチド模倣化合物及びその抗体−薬物コンジュゲート Active JP6671292B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361916680P 2013-12-16 2013-12-16
US61/916,680 2013-12-16
PCT/US2014/070654 WO2015095223A2 (en) 2013-12-16 2014-12-16 Peptidomimetic compounds and antibody-drug conjugates thereof

Publications (3)

Publication Number Publication Date
JP2017503011A JP2017503011A (ja) 2017-01-26
JP2017503011A5 true JP2017503011A5 (https=) 2018-02-01
JP6671292B2 JP6671292B2 (ja) 2020-03-25

Family

ID=52293248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558549A Active JP6671292B2 (ja) 2013-12-16 2014-12-16 ペプチド模倣化合物及びその抗体−薬物コンジュゲート

Country Status (10)

Country Link
US (1) US9999681B2 (https=)
EP (1) EP3082874A2 (https=)
JP (1) JP6671292B2 (https=)
KR (1) KR102354207B1 (https=)
CN (1) CN105873614B (https=)
BR (1) BR112016012410A2 (https=)
CA (1) CA2928952A1 (https=)
MX (1) MX371092B (https=)
RU (1) RU2689388C1 (https=)
WO (1) WO2015095223A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
KR102337414B1 (ko) 2013-12-16 2021-12-10 제넨테크, 인크. 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
AU2015358532C1 (en) * 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
CR20180243A (es) * 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
CN118436801A (zh) * 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017207540A1 (en) 2016-05-30 2017-12-07 Toxinvent Oü Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018103739A1 (zh) * 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 抗体药物偶联物、制备方法、中间体、药物组合物及应用
JP2020531430A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗体を標的とする抗ctla4プロボディ療法
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
PE20231104A1 (es) 2020-07-21 2023-07-19 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN113880731A (zh) * 2021-10-28 2022-01-04 成都市科隆化学品有限公司 一种Fmoc-D-Cit光学纯度的纯化方法及得到的产品
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
JP2024111822A (ja) * 2023-02-06 2024-08-19 日油株式会社 マレイミド基を有するアミン塩酸塩及びその製造方法
TW202528311A (zh) 2023-09-13 2025-07-16 日商安斯泰來製藥股份有限公司 包含具有g12d突變kras蛋白分解誘導作用之雜環化合物的抗體藥物複合體
WO2025168481A1 (en) * 2024-02-05 2025-08-14 Nerviano Medical Sciences S.R.L. Imino-anthracycline derivatives and methods

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6098584A (ja) 1983-11-02 1985-06-01 Canon Inc カメラ―体形vtr
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
AU6355090A (en) 1989-08-23 1991-04-03 Scripps Clinic And Research Foundation Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
AU9016591A (en) 1990-10-25 1992-05-26 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells
ATE194385T1 (de) 1991-03-29 2000-07-15 Genentech Inc Menschliche pf4a rezeptoren und ihre verwendung
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
JP3050424B2 (ja) 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US6153408A (en) 1991-11-15 2000-11-28 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
US5750370A (en) 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20020193567A1 (en) 1995-08-11 2002-12-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP3646191B2 (ja) 1996-03-19 2005-05-11 大塚製薬株式会社 ヒト遺伝子
EP0910636A1 (en) 1996-05-17 1999-04-28 Schering Corporation Human b-cell antigens, related reagents
JP2001505194A (ja) * 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6261791B1 (en) 1997-03-10 2001-07-17 The Regents Of The University Of California Method for diagnosing cancer using specific PSCA antibodies
EP0981541B1 (en) 1997-03-10 2004-06-02 The Regents Of The University Of California Psca: prostate stem cell antigen
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
WO1998051805A1 (en) 1997-05-15 1998-11-19 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO1998051824A1 (en) 1997-05-15 1998-11-19 Abbott Laboratories Reagents and methods useful for detecting disease of the urinary tract
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20020034749A1 (en) 1997-11-18 2002-03-21 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
ES2313779T3 (es) 1998-03-13 2009-03-01 The Burnham Institute Moleculas que migran a diversos organos o tejidos seleccionados.
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20020187472A1 (en) 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
WO2000012130A1 (en) 1998-08-27 2000-03-09 Smithkline Beecham Corporation Rp105 agonists and antagonists
JP4689781B2 (ja) 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
AU5963699A (en) 1998-10-02 2000-04-26 Mcmaster University Spliced form of (erb)b-2/neu oncogene
US20030091580A1 (en) 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69939553D1 (de) 1998-12-30 2008-10-23 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
CZ20012587A3 (cs) 1999-01-29 2002-05-15 Corixa Corporation Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
GB9905124D0 (en) 1999-03-05 1999-04-28 Smithkline Beecham Biolog Novel compounds
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7304126B2 (en) 1999-05-11 2007-12-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4952600A (en) 1999-06-03 2000-12-28 Takeda Chemical Industries Ltd. Screening method with the use of cd100
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
US7297770B2 (en) 1999-08-10 2007-11-20 Genentech, Inc. PRO6496 polypeptides
US7294696B2 (en) 1999-08-17 2007-11-13 Genentech Inc. PRO7168 polypeptides
CA2380355A1 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030129192A1 (en) 1999-09-10 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030206918A1 (en) 1999-09-10 2003-11-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
AU2048901A (en) 1999-11-29 2001-06-04 Trustees Of Columbia University In The City Of New York, The Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
EP1248800A2 (en) 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1239866A4 (en) 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP1244708B8 (en) 1999-12-23 2007-03-07 ZymoGenetics, Inc. Method for treating inflammation
NZ502058A (en) 1999-12-23 2003-11-28 Ovita Ltd Isolated mutated nucleic acid molecule for regulation of ovulation rate
AU783473B2 (en) 1999-12-23 2005-10-27 Zymogenetics Inc. Soluble interleukin-20 receptor
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7294695B2 (en) 2000-01-20 2007-11-13 Genentech, Inc. PRO10268 polypeptides
CA2398102A1 (en) 2000-01-21 2001-07-26 Corixa Corporation Compounds and methods for prevention and treatment of her-2/neu associated malignancies
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020142377A1 (en) 2000-02-22 2002-10-03 Glucksmann Maria Alexandra 18607, a novel human calcium channel
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1261743A2 (en) 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001249411B2 (en) 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
AU2001250412A1 (en) 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
US7279294B2 (en) 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
CN1420929A (zh) 2000-04-07 2003-05-28 阿瑞那制药公司 非内源性组成型活化的已知g蛋白偶联受体
US20030119115A1 (en) 2000-05-17 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001088133A2 (en) 2000-05-18 2001-11-22 Lexicon Genetics Incorporated Human semaphorin homologs and polynucleotides encoding the same
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001275437A1 (en) 2000-06-09 2001-12-17 Idec Pharmaceuticals Corporation Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
WO2001098351A2 (en) 2000-06-16 2001-12-27 Incyte Genomics, Inc. G-protein coupled receptors
EP1301524A1 (en) 2000-06-30 2003-04-16 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
EP1383892A2 (en) 2000-06-30 2004-01-28 Incyte Genomics, Inc. Human extracellular matrix and cell adhesion polypeptides
WO2002002624A2 (en) 2000-06-30 2002-01-10 Amgen, Inc. B7-like molecules and uses thereof
WO2002006339A2 (en) 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
US20040044179A1 (en) 2000-07-25 2004-03-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6891030B2 (en) 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
DE60134178D1 (de) 2000-07-28 2008-07-03 Ulrich Wissenbach Trp8 krebsmarker
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
WO2002013847A2 (en) 2000-08-14 2002-02-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
EP1366153A2 (en) 2000-08-14 2003-12-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
CA2420140A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1346040A2 (en) 2000-09-11 2003-09-24 Nuvelo, Inc. Novel nucleic acids and polypeptides
ATE333888T1 (de) 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
US7582293B2 (en) 2000-09-15 2009-09-01 Genentech, Inc. Anti-PRO6308 antibodies
US6613567B1 (en) 2000-09-15 2003-09-02 Isis Pharmaceuticals, Inc. Antisense inhibition of Her-2 expression
NZ525380A (en) 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1474528A4 (en) 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
ES2329012T3 (es) 2000-11-07 2009-11-20 Zymogenetics, Inc. Receptor del factor de necrosis tumoral humano.
US20020150573A1 (en) 2000-11-10 2002-10-17 The Rockefeller University Anti-Igalpha-Igbeta antibody for lymphoma therapy
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US20030119125A1 (en) 2001-01-16 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119126A1 (en) 2001-01-16 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス, インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
WO2002060317A2 (en) 2001-01-30 2002-08-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002064780A1 (en) 2001-02-12 2002-08-22 Bionomics Limited Dna sequences for human tumour suppressor genes
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
CA2443617C (en) 2001-04-17 2013-12-10 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
PL207087B1 (pl) 2001-04-26 2010-10-29 Biogen Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US20030078399A1 (en) 2001-05-11 2003-04-24 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
AU2002314901A1 (en) 2001-06-04 2002-12-16 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
JP2005518185A (ja) 2001-06-04 2005-06-23 キュラジェン コーポレイション 新規タンパク質およびそれをコード化する核酸
DE60237917D1 (de) 2001-06-05 2010-11-18 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
EP1402053A4 (en) 2001-06-05 2005-05-11 Exelixis Inc CHDS AS MODULATORS OF THE P53 PATH AND METHOD OF USE
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2002101075A2 (en) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2002102235A2 (en) 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20030108958A1 (en) 2001-06-28 2003-06-12 Rene De Waal Malefyt Biological activity of AK155
WO2003004529A2 (en) 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003003984A2 (en) 2001-07-05 2003-01-16 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2003055439A2 (en) 2001-07-18 2003-07-10 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
BR0211614A (pt) 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20030092013A1 (en) 2001-08-16 2003-05-15 Vitivity, Inc. Diagnosis and treatment of vascular disease
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US6902930B2 (en) 2001-08-29 2005-06-07 Vanderbilt University Human Mob-5 (IL-24) receptors and uses thereof
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20050004017A1 (en) 2001-09-18 2005-01-06 Yuval Reiss Methods and compositions for treating hcap associated diseases
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
CA2460621A1 (en) 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20030077644A1 (en) 2001-09-28 2003-04-24 Bing Yang Diagnosis and treatment of diseases caused by mutations in CD72
AU2002362454A1 (en) 2001-10-03 2003-04-14 Origene Technologies, Inc. Regulated breast cancer genes
US20050130117A1 (en) 2001-10-03 2005-06-16 Davis Cong L. Modulators of lymphocyte activation and migration
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003034984A2 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
CA2465268A1 (en) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
KR100996226B1 (ko) 2001-10-31 2010-11-24 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(bmp), bmp 수용체 및 bmp결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002339691A1 (en) 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders
AU2002349784A1 (en) 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES
AU2003213606A1 (en) 2002-03-01 2003-10-13 Exelixis, Inc. MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
US20050287147A1 (en) 2002-05-15 2005-12-29 Reinhard Ebner Cancer-linked gene as target for chemotherapy
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
WO2004000997A2 (en) 2002-03-19 2003-12-31 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003081210A2 (en) 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
JP2005520566A (ja) 2002-03-22 2005-07-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Cripto特異的抗体
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2005521429A (ja) 2002-03-25 2005-07-21 ユーエービー リサーチ ファウンデーション Fcレセプターホモログ、試薬およびこれらの使用
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
EP1572916A4 (en) 2002-04-05 2007-05-30 Agensys Inc NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2003089904A2 (en) 2002-04-17 2003-10-30 Baylor College Of Medicine Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
AU2003228869A1 (en) 2002-05-03 2003-11-17 Incyte Corporation Transporters and ion channels
WO2003101388A2 (en) 2002-05-30 2003-12-11 Bristol-Myers Squibb Company Human solute carrier family 7 member 11 (hslc7a11)
WO2003101283A2 (en) 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
AU2003239969A1 (en) 2002-06-04 2003-12-19 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003242633A1 (en) 2002-06-06 2003-12-22 Molecular Engines Laboratories Dudulin genes, non-human animal model: uses in human hematological disease
EP1513934B1 (en) 2002-06-06 2011-03-02 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
CA2488629A1 (en) 2002-06-07 2003-12-18 Avalon Pharmaceuticals, Inc Cancer-linked gene as target for chemotherapy
AU2003245441A1 (en) 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US20040022727A1 (en) 2002-06-18 2004-02-05 Martin Stanton Aptamer-toxin molecules and methods for using same
EP1539218A4 (en) 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
WO2004009622A2 (en) 2002-07-19 2004-01-29 Cellzome Ag Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2004011611A2 (en) 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
WO2004015426A1 (en) 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
MXPA05001933A (es) 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
AU2003278725A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
WO2004020595A2 (en) 2002-08-29 2004-03-11 Five Prime Therapeutics, Inc. Novel human polypeptides encoded by polynucleotides
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
JP2004113151A (ja) 2002-09-27 2004-04-15 Sankyo Co Ltd 癌遺伝子及びその用途
CA2500978A1 (en) 2002-10-03 2004-04-15 Mcgill University Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
AU2003288918A1 (en) 2002-10-04 2004-05-04 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP1578940A4 (en) 2002-11-13 2007-12-12 Genentech Inc METHOD AND COMPOSITIONS FOR DYSPLASED DIAGNOSIS
WO2004045553A2 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2004046342A2 (en) 2002-11-20 2004-06-03 Biogen Idec Inc. Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP1581641A4 (en) 2002-12-06 2006-11-15 Diadexus Inc COMPOSITIONS, SPREADING VARIATIONS AND METHODS RELATED TO OVARAL SPECIFIC GENES AND PROTEINS
JP2004198419A (ja) 2002-12-13 2004-07-15 Bayer Healthcare Llc Timp1を用いた検出方法
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
WO2004058171A2 (en) 2002-12-20 2004-07-15 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
AU2003299819A1 (en) 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
CA2512536A1 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2004065577A2 (en) 2003-01-14 2004-08-05 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
EP1583821A4 (en) 2003-01-15 2007-07-18 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004213432A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
PL2135881T3 (pl) 2005-06-20 2012-02-29 Genentech Inc Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
ES2708763T3 (es) * 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
EP2032606B1 (en) 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
FR2922106B1 (fr) * 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8580312B2 (en) * 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
BR112013027119A8 (pt) * 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9056910B2 (en) * 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
CN104540519B (zh) * 2012-05-21 2018-06-01 基因泰克公司 抗Ly6E抗体和免疫缀合物及使用方法
BR112015008365A2 (pt) * 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
KR102337414B1 (ko) 2013-12-16 2021-12-10 제넨테크, 인크. 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof

Similar Documents

Publication Publication Date Title
JP2017503011A5 (https=)
JP2017504606A5 (https=)
JP2017503009A5 (https=)
JP2015528818A5 (https=)
JP2015527318A5 (https=)
ES2988698T3 (es) Conjugados de fracciones de unión a la camptotecina
JP5314590B2 (ja) カンプトテシン結合部分
ES2918425T3 (es) Conjugados de anticuerpo-fármaco
ES2909486T3 (es) Sistemas de administración para liberación controlada de fármaco
ES2975330T3 (es) Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
JP2015527319A5 (https=)
JP2012509344A5 (https=)
JP2016512832A5 (https=)
JP2017522861A5 (https=)
JP2015531750A5 (https=)
JP2016512211A5 (https=)
JP2015523961A5 (https=)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2015534578A5 (https=)
NZ707543A (en) Pyrrolobenzodiazepine-antibody conjugates
JP2018516539A5 (https=)
JP2013542958A5 (https=)
JP2008546792A5 (https=)
JP2016530254A5 (https=)
JP2011500725A5 (https=)